Scarica l'app Stockscreener
4.33
0.00%
0.00
Dopo l'orario di chiusura:
4.33
Codexis Inc Borsa (CDXS) Ultime notizie
Codexis (STU:4QK) 3-Year FCF Growth Rate : -35.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Codexis to Present at Piper Sandler Healthcare Conference in December 2024 | CDXS Stock News - StockTitan
Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire
Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis adds biotech veteran Raymond De Vré to board - Investing.com India
Codexis Strengthens Board and Updates Bylaws - TipRanks
CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan
Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewswire
Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan
Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian
Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St
Benchmark Downgrades Codexis (CDXS) - MSN
CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com
Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com
Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia
abrdn plc Grows Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock - Investing.com India
Codexis to Participate in Upcoming Healthcare Conferences - The Manila Times
Codexis (NASDAQ:CDXS) Earns Hold Rating from Benchmark - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.17 - Yahoo Finance
Codexis, Inc. Announces Strong Third Quarter 2024 Financial Results - Defense World
Codexis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Codexis, Inc. (NASDAQ:CDXS) Q3 2024 Earnings Call Transcript - Insider Monkey
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Earnings call: Codexis reports revenue growth and strategic focus in Q3 2024 - Investing.com
Codexis Inc Q3 2024 Earnings: Revenue Hits $12.83M, Beating Esti - GuruFocus.com
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... - Yahoo Finance
Codexis Reports Strong Q3 Revenue Growth - TipRanks
Codexis: Q3 Earnings Snapshot - CT Insider
Codexis Reports Third Quarter 2024 Financial Results - The Manila Times
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):